The Committee for Medicinal Products for Human Use recently offered a positive opinion for Seqirus’s quadrivalent influenza vaccine (QIVc) in people aged nine years and older.

Subject to approval by the European Commission, Seqirus plans to launch the vaccine as Flucelvax Tetra in Europe in time for the 2019/20 season.

QIVc, licensed in the US in 2016, protects against four influenza strains: A(H3N2), A(H1N1) and two B strains.

Seqirus produces QIVc using cell-based technology which, the company says, means QIVc “avoids egg-adapted changes associated with traditional manufacturing methods” and “may therefore offer a closer match to circulating viruses than traditional egg-based influenza vaccines, with the potential to provide better protection in some seasons”.

Recommended

Keith Ridge to lead NHS over-prescribing review

The review will look to address ‘problematic polypharmacy’ and the management of non-reviewed repeat prescri...

Hancock warns HCPs against stockpiling

Healthcare professionals should not build stockpiles of their own and any “over-ordering” will be investigat...




This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.